DOSAGE / PROTOCOL RECORD
AOD-9604 dosage: doses, routes, and durations from the research protocols
A structured review of the oral, subcutaneous, and intra-articular doses studied across preclinical and clinical research — not a recommendation for human use.
AOD-9604 Dosage Protocols Studied in Research
AOD-9604 dosage research is documented entirely within the METAOD clinical program (oral route, human trials) and the Kwon & Park 2015 rabbit study (intra-articular route). All dosage data below is sourced from these controlled research protocols — not from clinical practice or anecdotal sources.
Human oral trials (METAOD program):
- 1 mg/day oral — the primary efficacy cohort in Phase IIa (12 weeks); produced 2.6 kg weight loss versus 0.8 kg placebo [8].
- 0.25 mg, 0.5 mg, and 1 mg/day oral — the three dose arms in Phase IIb OPTIONS study (24 weeks, n=536); no arm reached statistical significance versus placebo [9].
- 10 mg/day oral — tested in a Phase IIa cohort; produced smaller weight reduction than the 1 mg/day cohort, confirming a non-linear (inverted) dose-response [8].
Preclinical rodent models: Chronic multi-week systemic protocols in ob/ob mice and Zucker obese rats demonstrated body-weight and adipose-mass reduction [2][5]. Specific dose amounts per kilogram in these rodent studies were not extracted in the published summaries reviewed; the primary outcomes were body-weight change and fat-oxidation indices.
Intra-articular OA model (rabbit): 0.25 mg per injection, weekly, for 4–7 weeks via ultrasound-guided intra-articular injection [14]. The combination of AOD-9604 plus hyaluronic acid produced the strongest cartilage-regeneration outcome, outperforming either agent alone.
AOD-9604 Dosage Chart: Ranges Used in Clinical Trials
The following summarizes dose cohorts studied in clinical trials. Data sourced from Stier et al. 2013 [9] and the Clin Pharmacol Ther review [8].
| Dose | Route | Duration | Trial Phase | Primary Outcome |
|---|---|---|---|---|
| 1 mg/day | Oral | 12 weeks | Phase IIa | 2.6 kg vs 0.8 kg placebo — positive signal [8] |
| 10 mg/day | Oral | 12 weeks | Phase IIa | Less reduction than 1 mg/day; non-linear response [8] |
| 0.25 mg/day | Oral | 24 weeks | Phase IIb | No significant weight loss vs placebo [9] |
| 0.5 mg/day | Oral | 24 weeks | Phase IIb | No significant weight loss vs placebo [9] |
| 1 mg/day | Oral | 24 weeks | Phase IIb | No significant weight loss vs placebo [9] |
| 0.25 mg/injection | Intra-articular | 4–7 weeks (weekly) | Preclinical (rabbit) | Cartilage regeneration; reduced lameness [14] |
Note: Phase IIa results at 12 weeks did not replicate in the 24-week Phase IIb pivotal trial at equivalent or lower doses. The non-linear dose-response across the 0.25–10 mg oral range was not fully characterized mechanistically in the published record.
AOD-9604 Half-Life and Pharmacokinetics
Specific pharmacokinetic half-life data for AOD-9604 in humans is not available in the primary published literature reviewed for this site. The 2014 safety and metabolism paper by Moré and Kenley references pharmacokinetic evaluations conducted in non-clinical species as part of the GRAS dossier [11], but specific half-life values from these non-clinical studies were not extracted in the publicly available paper abstract and were not identified in the peer-reviewed literature base compiled during research for this site.
Oral bioavailability: the clinical program used an oral tablet formulation for all human efficacy trials. Subcutaneous injection was also studied in research contexts; subcutaneous administration is generally expected to produce higher peptide bioavailability than oral administration, but a comparative human pharmacokinetic study for these two routes was not identified in the published literature reviewed.
The compound's fat-metabolism effects in rodent models were observed with chronic multi-week dosing, consistent with a mechanism requiring sustained receptor upregulation (ADRB3) rather than acute receptor occupancy [6]. This pharmacodynamic observation is not equivalent to a characterized half-life value and should not be interpreted as one.
AOD-9604 reconstitution methods in research protocols
Research protocols for injectable AOD-9604 describe dissolution of lyophilized powder in bacteriostatic water or dilute acetic acid at a concentration of 1–2 mg/mL [dosage_research_context]. This is consistent with standard peptide reconstitution practice for small hydrophilic peptides. Lyophilized powder is stable at room temperature for extended periods. Reconstituted peptide solution requires refrigeration at 2–8°C and should be used within 28 days per standard peptide-handling protocols.
No primary-study-specific reconstitution protocol for AOD-9604 was identified in the peer-reviewed literature reviewed for this site. The above guidance reflects standard-of-practice for research-use peptide reconstitution, not a specifically published AOD-9604 protocol.
Timing of AOD-9604 administration in research protocols
The METAOD human oral trial protocols administered doses once daily. Some animal studies used pre-exercise timing protocols to assess potential lipolytic synergy with exercise-induced metabolic demands. No published clinical study compared morning-fasted versus evening or fed-state administration in humans, and no head-to-head timing-comparison study was identified in the literature reviewed.
The 24-week OPTIONS Phase IIb study used standard once-daily oral dosing [9]. Intra-articular injections in the rabbit OA model were administered weekly [14].
How long was AOD-9604 studied in clinical trials?
The longest controlled human trial in the METAOD program was 24 weeks (the Phase IIb OPTIONS study, n=536) [9]. Phase IIa trials ran 12 weeks. No safety signals emerged at any duration studied; the safety and tolerability profile was indistinguishable from placebo at all time points reviewed [10]. No controlled human data beyond 24 weeks of continuous dosing is available in the published literature reviewed.
The AOD-9604 dosage protocols above cover the full range of doses and durations studied. For the safety record across this period, see AOD-9604 side effects and safety profile.
Dosing frequency studied in clinical protocols
Once-daily oral administration was the standard in all METAOD human trials [9]. Weekly intra-articular injection was the protocol in the rabbit OA study [14]. Five-days-on two-days-off cycling was used in some rodent studies; daily continuous administration was used in others. No comparative frequency study — daily versus alternate-day versus cycling — was identified in the published human clinical literature reviewed.
Administration route in AOD-9604 studies included oral tablet (all human clinical trials), subcutaneous injection (research use; pharmacokinetically expected to deliver higher bioavailability than oral but no comparative human PK study was identified), intra-articular injection (rabbit OA study and the ongoing NCT07225829 human trial), and transdermal (licensed by Phosphagenics Ltd for cosmeceutical use in 2009; no peer-reviewed human efficacy data identified for this route).
Onset of action: what the research shows
No validated human onset-of-action timeline for AOD-9604 is established in the published literature. Rodent models show progressive fat-mass reduction and elevated fat-oxidation markers over multi-week chronic treatment periods [5][6]. In the beta-3 AR knockout experiment, acute energy expenditure was elevated within the short-term measurement window, while the chronic body-weight effect required sustained ADRB3 upregulation over the full treatment period [6]. These preclinical kinetics do not translate directly to a human onset timeline.
The Phase IIa human trial measured outcomes at 12 weeks — the first published human efficacy data point. Whether the 2.6 kg versus 0.8 kg placebo difference at that endpoint had accrued gradually across the 12 weeks or was concentrated in a specific window was not reported in the published summaries reviewed [8].